Lucid Diagnostics报告第四季度初步结果

• Lucid Diagnostics (NASDAQ:LUCD) said Monday its fourth quarter EsoGuard revenue was $1.04 million.
• The company said its CLIA-certified clinical laboratory performed 2,201 commercial EsoGuard Esophageal DNA Tests in Q4.
• GAAP net loss for the fourth quarter was about $10.8 million, or $(0.26) per common share.
• Lucid had cash and cash equivalents of $18.9 million as of December 31, 2023.
• Press Release.

More on Lucid Diagnostics

• Seeking Alpha’s Quant Rating on Lucid Diagnostics
• Historical earnings data for Lucid Diagnostics
• Financial information for Lucid Diagnostics